Cepadacursen sodium
As of the edition of 20 October 2026, Cepadacursen sodium is an oligonucleotide: went quiet in 2020; acts on PCSK9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Oligonucleotide
- Registered trials
- 2, 0 stopped early
- Disease areas
- Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Cepadacursen sodium.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 | Q8NBP7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Civi Biopharma | Lead sponsor of trials | 2018 to now |